JP2018512413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512413A5 JP2018512413A5 JP2017549326A JP2017549326A JP2018512413A5 JP 2018512413 A5 JP2018512413 A5 JP 2018512413A5 JP 2017549326 A JP2017549326 A JP 2017549326A JP 2017549326 A JP2017549326 A JP 2017549326A JP 2018512413 A5 JP2018512413 A5 JP 2018512413A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021173052A JP2022003103A (ja) | 2015-03-19 | 2021-10-22 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510119944.5 | 2015-03-19 | ||
| CN201510119944.5A CN106146508A (zh) | 2015-03-19 | 2015-03-19 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| PCT/CN2016/000149 WO2016145935A1 (zh) | 2015-03-19 | 2016-03-18 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173052A Division JP2022003103A (ja) | 2015-03-19 | 2021-10-22 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512413A JP2018512413A (ja) | 2018-05-17 |
| JP2018512413A5 true JP2018512413A5 (enExample) | 2019-04-04 |
| JP7012534B2 JP7012534B2 (ja) | 2022-02-14 |
Family
ID=56918303
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549326A Active JP7012534B2 (ja) | 2015-03-19 | 2016-03-18 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
| JP2021173052A Pending JP2022003103A (ja) | 2015-03-19 | 2021-10-22 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173052A Pending JP2022003103A (ja) | 2015-03-19 | 2021-10-22 | 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3272752A4 (enExample) |
| JP (2) | JP7012534B2 (enExample) |
| KR (2) | KR20220110872A (enExample) |
| CN (4) | CN106146508A (enExample) |
| AU (2) | AU2016232923B2 (enExample) |
| BR (1) | BR112017019790B1 (enExample) |
| CA (2) | CA2980016C (enExample) |
| EA (2) | EA037058B1 (enExample) |
| IL (1) | IL254435B2 (enExample) |
| MX (1) | MX2017011836A (enExample) |
| WO (1) | WO2016145935A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| ES3006132T3 (en) | 2016-11-15 | 2025-03-17 | Hangzhou Healzen Therapeutics Co Ltd | Selective bruton's tyrosine kinase inhibitor and use thereof |
| CN106831788B (zh) * | 2017-01-22 | 2020-10-30 | 鲁南制药集团股份有限公司 | 伊布替尼精制方法 |
| US10738056B2 (en) * | 2017-09-15 | 2020-08-11 | Aduro Biotech Inc. | Pyrazolopyrimidinone compounds and uses thereof |
| TW201922256A (zh) * | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| WO2019127008A1 (zh) * | 2017-12-26 | 2019-07-04 | 清华大学 | 一种靶向降解btk的化合物及其应用 |
| JP2021512059A (ja) * | 2018-01-29 | 2021-05-13 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法 |
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| CN108992454B (zh) * | 2018-06-20 | 2020-06-02 | 合肥医工医药股份有限公司 | 一种治疗皮肤炎症性疾病的复方药物组合物 |
| CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| CN109369654A (zh) * | 2018-11-20 | 2019-02-22 | 山东大学 | 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用 |
| KR102819183B1 (ko) * | 2019-03-29 | 2025-06-13 | 한미약품 주식회사 | 퓨로피리미딘 화합물의 산 부가염의 결정형 |
| BR112022006394A2 (pt) | 2019-10-02 | 2022-07-26 | Tolremo Therapeutics Ag | Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer |
| CN110845500B (zh) * | 2019-10-09 | 2021-05-11 | 清华大学 | 靶向btk降解化合物在治疗自身免疫系统疾病中的应用 |
| CN110724143B (zh) * | 2019-10-09 | 2021-03-23 | 清华大学 | 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用 |
| EP4171556A1 (en) * | 2020-06-25 | 2023-05-03 | Tolremo Therapeutics AG | A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc |
| CN115916191B (zh) * | 2020-06-25 | 2026-06-23 | 新基公司 | 用组合疗法治疗癌症的方法 |
| AU2021298154A1 (en) | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| WO2021260110A1 (en) | 2020-06-25 | 2021-12-30 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
| CN113943312A (zh) * | 2020-07-17 | 2022-01-18 | 轶诺(浙江)药业有限公司 | 一类肠道裂解型共药及其制备和用途 |
| RS66874B1 (sr) * | 2020-09-17 | 2025-06-30 | Novartis Ag | Jedinjenja i kompozicije kao inhibitori sppl2a |
| CA3196886A1 (en) * | 2020-11-04 | 2022-05-12 | Yoram Devary | Polypeptides for use in the treatment and prevention of neurodegenerative diseases |
| CA3212085C (en) | 2021-04-07 | 2025-02-11 | Tolremo Therapeutics Ag | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER |
| CN114507236A (zh) * | 2022-02-28 | 2022-05-17 | 山东中医药大学 | mTOR蛋白降解靶向嵌合体及其制备方法和应用 |
| AU2023254266A1 (en) * | 2022-04-12 | 2024-10-17 | Hefei Youyuan Pharmaceutical Co., Ltd. | Novel use of pyrazolopyrimidine compound |
| CN117045800A (zh) * | 2022-05-06 | 2023-11-14 | 上海科技大学 | mTOR抑制剂增强靶向蛋白降解药物功效的应用 |
| CN116024346A (zh) * | 2023-02-10 | 2023-04-28 | 复旦大学附属华山医院 | SLCO1B1 rs2306283位点多态性在评价甲氨蝶呤所致骨髓抑制发生风险中的应用 |
| CN117510494B (zh) * | 2023-11-07 | 2024-04-19 | 桂林医学院附属医院 | β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| EP2139487B1 (en) * | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CN102159214A (zh) * | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| AU2012255860C1 (en) | 2011-05-17 | 2015-12-10 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
| CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| CA2879400A1 (en) | 2012-07-30 | 2014-02-06 | Concert Pharmaceuticals, Inc. | Deuterated ibrutinib |
| US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| WO2014113942A1 (en) * | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| WO2014143807A2 (en) * | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CA2908954C (en) | 2013-04-17 | 2021-08-03 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
| EP2999702A4 (en) * | 2013-05-21 | 2017-01-11 | Jiangsu Medolution Ltd. | Substituted pyrazolopyrimidines as kinases inhibitors |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
-
2015
- 2015-03-19 CN CN201510119944.5A patent/CN106146508A/zh active Pending
-
2016
- 2016-03-18 CA CA2980016A patent/CA2980016C/en active Active
- 2016-03-18 BR BR112017019790-1A patent/BR112017019790B1/pt active IP Right Grant
- 2016-03-18 KR KR1020227026364A patent/KR20220110872A/ko not_active Ceased
- 2016-03-18 IL IL254435A patent/IL254435B2/en unknown
- 2016-03-18 CN CN201680017009.0A patent/CN107406454B/zh active Active
- 2016-03-18 EA EA201792066A patent/EA037058B1/ru unknown
- 2016-03-18 JP JP2017549326A patent/JP7012534B2/ja active Active
- 2016-03-18 MX MX2017011836A patent/MX2017011836A/es unknown
- 2016-03-18 AU AU2016232923A patent/AU2016232923B2/en active Active
- 2016-03-18 EP EP16764117.4A patent/EP3272752A4/en active Pending
- 2016-03-18 CA CA3191171A patent/CA3191171A1/en active Pending
- 2016-03-18 WO PCT/CN2016/000149 patent/WO2016145935A1/zh not_active Ceased
- 2016-03-18 KR KR1020177025465A patent/KR102428387B1/ko active Active
- 2016-03-18 CN CN202111303221.2A patent/CN114790209A/zh active Pending
- 2016-03-18 CN CN202010319886.1A patent/CN111349099A/zh active Pending
- 2016-03-18 EA EA202092671A patent/EA202092671A1/ru unknown
-
2020
- 2020-11-24 AU AU2020277128A patent/AU2020277128B2/en active Active
-
2021
- 2021-10-22 JP JP2021173052A patent/JP2022003103A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017008088A5 (enExample) | ||
| MX2021011472A (es) | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. | |
| JP2016533366A5 (enExample) | ||
| PE20160995A1 (es) | Inhibidores de syk | |
| MY201673A (en) | Polycyclic amide derivatives as cdk9 inhibitors | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| MX2020001832A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
| JP2009514881A5 (enExample) | ||
| JP2015535851A5 (enExample) | ||
| RU2015118135A (ru) | Содержащие заместители бензольные соединения | |
| PH12019501639B1 (en) | Jak1 selective inhibitors | |
| JP2015500884A5 (enExample) | ||
| JP2016521280A5 (enExample) | ||
| RU2008122046A (ru) | Аминопиримидины в качестве ингибиторов киназ | |
| JP2017524668A5 (enExample) | ||
| JP2016504365A5 (enExample) | ||
| JP2009514880A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| UA118261C2 (uk) | Хімічні сполуки | |
| JP2013542261A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| JP2015520770A5 (enExample) | ||
| GEP20207128B (en) | Aminothiazole derivatives useful as antiviral agents | |
| MY190849A (en) | Methods of treating multiple sclerosis |